Lithera’s product, LIPO-102, is a physician-administered, injectable dosage form of our drug product for local, selective fat reduction therapy (injection lipoplasty), currently being developed for thyroid-related exophthalmos (protrusion of the eye from the orbit).
Competitive Advantages of LIPO-102:
Lithera’s LIPO-102 product has competitive and differentiating advantages over other drugs and devices being developed for local selective fat reduction.- Potential safety: Our products are based on FDA-registered compounds with a proven track record of safety in other indications.
- Non-ablative approach: Our therapeutic result is not achieved by surgical or destructive means. Our product stimulates the natural metabolic process that leads to a reduction of fat tissue. We believe this mechanism has the potential to limit pain and complications otherwise associated with ablative mechanisms, and makes it possible to treat the delicate tissues of the orbit.
- Selectivity and specificity: Our drug product has a high affinity for receptors located on the fat tissue leading to a location specific and selective result. Ablative products can indiscriminately destroy tissue (e.g. skin) that comes in contact with the drug or device.
- Rapid results and no down time: Because the body does not need to heal from an ablative insult, recovery time may be minimal and results may be seen quickly.
- Simplicity: The product will be delivered by a simple injection. In contrast to devices, there is no complex equipment that must be purchased and maintained and requires training to use.